Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $80.5 million.

  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity rose 3682.56% to $80.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.3 million, marking a year-over-year increase of 4270.88%. This contributed to the annual value of $68.9 million for FY2024, which is 5126.78% up from last year.
  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity amounted to $80.5 million in Q3 2025, which was up 3682.56% from $89.5 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $101.3 million in Q1 2022 and a low of $40.1 million during Q1 2024
  • Moreover, its 4-year median value for Liabilities and Shareholders Equity was $64.6 million (2024), whereas its average is $67.9 million.
  • In the last 5 years, Corvus Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 4254.42% in 2023 and then skyrocketed by 5126.78% in 2024.
  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $68.2 million in 2022, then plummeted by 33.25% to $45.6 million in 2023, then soared by 51.27% to $68.9 million in 2024, then grew by 16.79% to $80.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $80.5 million for Q3 2025, versus $89.5 million for Q2 2025 and $59.4 million for Q1 2025.